Download the Agenda


Speaker Information

 Cris Kamperschroer
Cris Kamperschroer Senior Principal Scientist Pfizer


Main Conference Day 1

9:05 AM Chairman’s Opening Remarks

The chair will set the mission statement for the two days ahead, introduce the key themes and highlight the outline of the day. Take this opportunity to get to know your peers and discuss your priorities for the next two days.

Main Conference Day 2

9:00 AM Chairman's Recap of Day 1

10:30 AM Combining Targeted Therapy and Immune Checkpoint Inhibitors in the Treatment of Metastatic Melanoma

Metastatic melanoma treatment has considerably progressed in
the past five years with the introduction of targeted therapy
(BRAF and MEK inhibitors) and immune checkpoint blockade
(anti-CTLA4, anti-PD-1, and anti-PD-L1). While each treatment
modality has limitations, synergy may exist when targeted
therapy is combined with immunotherapy.
• An overview of the rationale and evidence for the potential
synergy between targeted therapy and immune checkpoint
blockade
• Addressing challenges and directions for future studies

Sponsorship Opportunities

Resource Center

Visit the Resource Center for complimentary industry related content!

IDGA

Become a Pharma IQ Member and receive our weekly newsletter!